SB273 Alabama 2025 Session

Summary

Primary Sponsor

April WeaverSenator

Republican

Session

2025 Regular Session

Title

Controlled substances; regulate sale of nonpsychoactive consumable hemp products by Agriculture Department; require sale of products only in pharmacies; add psychoactive derivatives of hemp as Schedule I drug

Summary

SB273 would regulate hemp consumable products by requiring in-state, pharmacy-only sales with testing and tracking, classify psychoactive hemp derivatives as Schedule I, and repeal the ban on selling psychoactive cannabinoids to minors.

What This Bill Does

Psychoactive cannabinoids derived from hemp would be classified as Schedule I substances, while nonpsychoactive cannabinoids would be exempt. Ingestible CBD or nonpsychoactive hemp products could only be sold in licensed pharmacies certified by the State Board of Pharmacy and would require a certificate of analysis from testing. The bill creates a seed-to-sale tracking system for hemp and consumable products, requires testing with ISO/IEC 17025-accredited labs, and mandates annual board inspections; only Alabama-grown hemp can be used, with costs borne by cultivators and processors. It also repeals the existing prohibition on selling psychoactive cannabinoids to minors and sets implementation dates.

Who It Affects

• General consumers of hemp products in Alabama, who would face pharmacy-only sales, mandatory testing and analysis, and in-state hemp sourcing (and who may be affected by the repeal of the minor-sale ban).
• Hemp growers, processors, testing laboratories, and licensed pharmacies, along with state regulators (Board of Pharmacy and Department of Agriculture), who would implement tracking, testing protocols, certifications, inspections, and cost allocations.

Key Provisions

• Classification and exemptions: psychoactive cannabinoids derived from hemp would be listed as Schedule I controlled substances, while nonpsychoactive cannabinoids derived from or found in hemp would be exempt from Schedule I.
• Sales, testing, and tracking framework: consumable hemp products containing CBD or nonpsychoactive cannabinoids could only be sold in licensed pharmacies certified by the Board of Pharmacy, must be tested with a certificate of analysis, and would require seed-to-sale tracking of hemp production and product testing with in-state cultivation; the bill also repeals the minor-purchase ban and establishes inspection and cost responsibilities.

AI-generated summary using openai/gpt-5-nano on Feb 22, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Crimes & Offenses